AI in Precision Oncology Market By Solution Type (AI-Powered Diagnostic and Biomarker Tools, Treatment Recommendation Engines, Predictive Modeling Platforms, Workflow Optimization and Trial Matching Tools, Drug Discovery AI); By Cancer Type (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Hematologic Malignancies); By Technology (Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, Reinforcement Learning); By End User (Hospitals and Cancer Centers, Biopharma Companies, Research Institutes, Startups, Government Agencies); By Geography, Segment Revenue Estimation and Forecast, 2026–2032

AI in Precision Oncology Market: Multimodal Intelligence Reshapes Cancer Diagnosis and Treatment Decisions

The Global AI in Precision Oncology Market was valued at USD 1.25 billion in 2025 , The market is projected to generate USD 8.54 billion by 2032, expanding at a CAGR of 31.59% from 2026 to 2032, according to a central-case model by Strategic Market Research.

 

Cancer care produces genomic sequences, pathology slides, radiology scans, laboratory results, treatment histories, physician notes, and longitudinal outcomes at a scale that cannot be interpreted efficiently through manual review alone. AI creates commercial value when these datasets are converted into a biomarker, treatment recommendation, trial match, prognosis, or drug-development decision.

 

The clinical addressable base continues to expand. The International Agency for Research on Cancer estimated almost 20 million new cancer cases and 9.7 million cancer deaths in 2022. Annual new cases are projected to reach approximately 35 million by 2050, representing a 77% increase from 2022. Hospitals, diagnostic laboratories, and drug developers therefore face a growing interpretation burden without an equivalent expansion in molecular pathologists, radiologists, bioinformaticians, or clinical-research staff.

 

The Multimodal Intelligence Stack Becomes Oncology’s Control Layer

Single-purpose algorithms can classify an image or flag a genomic alteration, but precision-oncology decisions rarely depend on one data type. Higher-value platforms combine genomics, transcriptomics, proteomics, digital pathology, radiology, laboratory records, electronic health records, and treatment outcomes to build a patient-specific representation of tumour biology.

Multimodal models can identify relationships between tissue morphology, immune-cell distribution, molecular alterations, disease progression, treatment resistance, and survival outcomes. Recent oncology reviews position multimodal integration as a practical route toward biomarker discovery and individualized treatment selection, while retaining specialist oversight for final clinical decisions.

Predictive modeling platforms are estimated to account for USD 264 million, or 16.1% of the market, in 2026 and are forecast to reach USD 1.44 billion by 2032 at a 32.7% CAGR. Demand is moving toward platforms that can be reused across patient stratification, recurrence forecasting, response prediction, and biopharma research rather than algorithms limited to one diagnostic task.

A hospital may initially purchase image or genomic analytics, while a pharmaceutical company can use the same underlying data architecture for cohort selection, companion-diagnostic development, indication expansion, and real-world evidence. This supports software subscriptions, testing fees, data licences, research services, and milestone-based contracts within the same platform.

 

Routine H&E Slides Become Software-Defined Biomarkers

Digital pathology represents one of the most commercially mature applications because routine haematoxylin and eosin slides already exist across oncology workflows. Deep-learning models can quantify tumour architecture, grade lesions, map immune-cell relationships, and screen for molecular features such as microsatellite instability without requiring a separate molecular test for every patient.

A 2025 digital-pathology study involving 212 patients and 416 slides developed an AI model for predicting microsatellite instability-high status in gastroesophageal junction adenocarcinoma. The leading model achieved an AUC of 93.3%, sensitivity of 84.1%, and specificity of 95.2%, although the single-centre design still requires broader external validation. A systematic review of MSI prediction from whole-slide images reported a maximum AUC of 0.93 in colorectal cancer studies.

AI-powered diagnostic and biomarker tools are estimated to lead the solution market with USD 634 million in 2026 revenue and a 38.6% share. The segment is projected to reach USD 2.86 billion by 2032, expanding at a 28.6% CAGR.

Lunit uses computational pathology to analyse tumour microenvironments, immunohistochemistry biomarkers, protein expression, and genotype-associated features. Its 2025 business report recorded KRW 10.1 billion in oncology-service revenue, compared with KRW 3.43 billion in 2024, while the company reported 159% growth across its oncology business. Commercial growth reflects pharmaceutical demand for biomarker development and image-analysis services rather than academic use alone.

Regulated pathology products are also moving beyond lesion detection. The FDA granted De Novo authorization to ArteraAI Prostate in July 2025. The software analyses digitized biopsy slides and clinical variables to estimate ten-year risks of distant metastasis and prostate-cancer-specific mortality. In May 2026, the FDA cleared ArteraAI Breast for risk stratification in early-stage hormone receptor-positive, HER2-negative invasive breast cancer.

These authorizations expand the addressable market from workflow assistance toward prognosis, treatment-benefit prediction, and risk-based decision support.

 

AI Turns EHR Noise into Trial Candidates

Clinical-trial eligibility is distributed across pathology reports, genomic results, previous treatments, laboratory values, disease stage, clinical notes, and protocol-specific inclusion and exclusion criteria. Manual screening can delay patient identification and consumes research-coordinator and physician time.

TrialMatchAI reported that 92% of evaluated oncology patients had at least one relevant trial among the top 20 recommendations, while expert review validated more than 90% accuracy in criterion-level eligibility classification. The MSK-MATCH breast cancer workflow evaluated 88,518 clinical documents from 731 patients, achieved 98.6% patient-level eligibility accuracy, and reduced manual review for selected cases from approximately 20 minutes to 43 seconds when AI-generated explanations were prepopulated.

Workflow optimization and trial matching tools are estimated to generate USD 258 million in 2026, representing a 15.7% market share. Revenue is forecast to reach USD 1.47 billion by 2032 at a 33.7% CAGR.

Hospitals can use these platforms to identify eligible patients before trial opportunities are missed, while sponsors benefit from faster cohort formation and improved recruitment for biomarker-defined studies. Revenue comes from enterprise licences, recruitment contracts, EHR integration, data abstraction, and sponsor-funded study programmes.

Human review remains necessary because an apparent match may fail on previous treatment, organ function, timing, comorbidity, or site-level protocol interpretation. Products that present traceable eligibility evidence are commercially better positioned than systems returning unsupported rankings. Research on human–AI prescreening also indicates that combined review can outperform AI-only workflows.

 

From Mutation Lists to Treatment-Response Forecasting

Genomic interpretation remains central to precision oncology, but the market is moving beyond systems that simply connect a mutation with an approved drug. Treatment engines increasingly combine molecular variants with histology, imaging, blood markers, treatment history, and real-world outcomes to estimate response, resistance, recurrence, and toxicity.

Treatment recommendation engines are estimated at USD 296 million in 2026, equal to 18.0% of market revenue, and are projected to reach USD 1.54 billion by 2032 at a 31.6% CAGR.

AI models are being investigated for immune-checkpoint response prediction, treatment-resistance modelling, single-cell drug-response analysis, and the interpretation of variants whose clinical significance remains uncertain. The higher-value commercial products will be those that explain why a therapy was prioritized, identify the evidence used, and quantify uncertainty rather than producing an unexplained treatment list.

Liquid-biopsy analysis adds another revenue opportunity. Algorithms can combine cell-free DNA, methylation signatures, clinical data, and clonal-haematopoiesis filters to improve tumour detection and avoid incorrectly assigning blood-derived variants to the tumour.

 

Biopharma Creates a Second Revenue Engine

Biopharma companies use oncology AI for target discovery, biomarker development, indication selection, synthetic control arms, trial matching, patient stratification, site selection, and real-world evidence. These programmes can produce larger contract values than individual hospital licences because they combine proprietary datasets, analytical services, modelling, and multi-year development work.

Biopharma companies are estimated to contribute USD 534 million, or 32.5% of market revenue, in 2026. The segment is forecast to reach USD 3.04 billion by 2032 at a 33.6% CAGR, narrowing the revenue gap with hospitals and cancer centres.

Tempus reported approximately USD 1.3 billion in total revenue during 2025, including USD 955.4 million from diagnostics and USD 316.4 million from data and applications. Oncology testing volume increased 26%, while the company ended the year with more than USD 1.1 billion in remaining contract value. In the first quarter of 2026, total revenue increased 36.1% year over year and oncology volume increased 28%.

Caris Life Sciences raised approximately USD 494 million through its June 2025 initial public offering. The company sold 23.5 million shares at USD 21 and reached a valuation of approximately USD 7.66 billion at its market debut. Caris has built a multimodal database covering more than one million patient cases and over 6.5 million completed tests.

Capital is being directed toward sequencing capacity, longitudinal clinical datasets, foundation models, regulated software, and pharmaceutical partnerships. Access to linked molecular and outcomes data consequently creates a stronger competitive barrier than algorithm development alone.

 

Revenue Pools Form Across the AI Oncology Stack

Solution Type: Diagnostic AI Leads While Drug Discovery Accelerates

Diagnostic and biomarker tools retain the largest revenue base because pathology and imaging workflows already have defined buyers, measurable outputs, and established regulatory pathways.

Drug discovery AI remains smaller but is expected to record the fastest solution-level growth. The segment is estimated at USD 187 million in 2026, representing an 11.4% share, and is forecast to reach USD 1.22 billion by 2032 at a 36.7% CAGR. Clinical translation remains dependent on toxicity testing, synthesis feasibility, pharmacokinetics, external validation, and successful trial execution.

 

Cancer Type: Lung Cancer Anchors Spending

Lung cancer represents the largest application because treatment selection depends on multiple genomic drivers, immune biomarkers, pathology characteristics, radiology findings, and acquired resistance patterns.

Lung cancer applications are estimated to generate USD 466 million in 2026, equal to a 28.5% market share, and are projected to reach USD 2.43 billion by 2032 at a 31.7% CAGR.

Breast cancer is estimated at USD 376 million in 2026, followed by prostate cancer at USD 281 million, colorectal cancer at USD 270 million, and hematologic malignancies at USD 248 million. Prostate cancer is forecast to grow at approximately 32.7% annually as AI-based pathology risk tools move into regulated clinical use.

 

Technology: Deep Learning Owns the Image Layer

Deep learning leads image-intensive applications across pathology, radiology, spatial biology, and radiogenomics.

Deep learning is estimated to hold a 35.7% share with USD 587 million in 2026 revenue and is forecast to reach USD 2.91 billion by 2032 at a 30.6% CAGR.

Machine learning is estimated at USD 417 million in 2026, computer vision at USD 296 million, and natural language processing at USD 270 million. NLP is projected to expand at a 35.7% CAGR as trial matching, chart abstraction, report interpretation, and clinical-document search become embedded in oncology workflows. Reinforcement learning remains the smallest technology segment but could grow at approximately 39.8% from a limited base as adaptive treatment and drug-design applications mature.

 

End User: Hospitals Hold Scale While Startups Move Fastest

Hospitals and cancer centres remain the largest buyers because they purchase diagnostic software, clinical decision support, trial-matching platforms, pathology tools, and workflow systems.

Hospitals and cancer centres are estimated to account for USD 645 million and 39.4% of the market in 2026, rising to USD 3.06 billion by 2032 at a 29.6% CAGR.

Research institutes are estimated at USD 228 million in 2026, startups at USD 135 million, and government agencies at approximately USD 97 million. Startup demand is projected to grow at about 35.7% annually as emerging companies license datasets, cloud infrastructure, foundation models, and specialized analytical tools.

 

The Trust Stack Determines Clinical Adoption

The FDA Oncology Center of Excellence established its Oncology Artificial Intelligence Program in 2023 in response to growing use of AI in oncology drug development and regulatory submissions. FDA guidance issued in January 2025 introduced a risk-based framework for assessing the credibility of AI models used to support decisions involving drugs and biological products. The agency has also proposed lifecycle expectations for AI-enabled medical-device software.

Commercial adoption depends on external validation across hospitals, scanners, patient groups, tissue-processing methods, and EHR structures. Models trained on narrow datasets can lose performance when deployed in populations or workflows that differ from the original training environment.

Suppliers must also address explainability, hallucination, data ownership, privacy, cybersecurity, auditability, and liability. Quality systems, local validation, specialist oversight, and post-deployment performance monitoring will carry greater commercial weight than benchmark accuracy alone.

 

Regional Growth Map: North America Leads, Asia-Pacific Accelerates

North America is estimated to generate USD 713 million in 2026, representing a 43.5% share. The regional market is forecast to reach USD 3.47 billion by 2032 at a 30.2% CAGR. The region benefits from major oncology data platforms, pharmaceutical sponsors, academic cancer centres, FDA-authorized products, venture funding, and established genomic-testing infrastructure.

Europe is estimated at USD 437 million in 2026 and is projected to reach USD 2.07 billion by 2032 at a 29.6% CAGR. Expansion depends on digital-pathology adoption, multicentre validation, biobank access, pharmaceutical research partnerships, and compliance with European data and medical-device requirements.

Asia-Pacific is estimated to account for USD 373 million in 2026 and is forecast to reach USD 2.32 billion by 2032, recording the fastest regional CAGR of 35.7%. Hospital digitization, large cancer populations, government-supported AI programmes, expanding sequencing access, and regional companies such as Lunit support faster adoption.

Latin America and the Middle East and Africa are estimated to generate a combined USD 120 million in 2026, rising to approximately USD 684 million by 2032 at a 33.6% CAGR. Adoption will initially concentrate in private hospital networks, academic centres, national genomics programmes, and multinational pharmaceutical trials.

 

The Data Moat Defines Competitive Power

Competition includes integrated precision-medicine platforms such as Tempus and Caris; molecular diagnostics providers; digital-pathology companies including Lunit, Paige, Ibex, and Artera; trial-matching specialists; cloud and data-infrastructure providers; and pharmaceutical-led computational biomarker programmes.

Tempus combines clinical testing, multimodal data, AI applications, and pharmaceutical contracts. Caris integrates tissue and blood profiling with clinicogenomic information. Lunit concentrates on computational pathology and biomarker development, while Artera is building regulated multimodal prognosis and treatment-benefit tools.

Platform compatibility, access to longitudinal outcomes, regulatory authorization, reimbursement, and evidence generated across multiple institutions will determine competitive durability. Companies embedded in clinical and pharmaceutical workflows are better protected from algorithm commoditization than suppliers offering isolated models.

 

2032 Outlook: Revenue Moves Toward Decision-Linked AI

Growth through 2032 will concentrate in products connected to a funded decision: selecting a therapy, identifying a biomarker-positive patient, finding a clinical trial, reducing pathology workload, monitoring residual disease, or improving drug development.

Digital twins, autonomous oncology agents, and fully simulated drug-response systems remain early-stage commercial opportunities. Prospective validation, accountability, representative datasets, interpretability, and specialist oversight remain necessary before these systems can influence treatment without substantial human review.

 

AI In Precision Oncology Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.25 Billion
Revenue Forecast in 2032	USD 8.54 Billion
Overall Growth Rate	CAGR of 31.59% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Solution Type, By Cancer Type, By Technology, By End User, By Geography
By Solution Type	AI-Powered Diagnostic and Biomarker Tools, Treatment Recommendation Engines, Predictive Modeling Platforms, Workflow Optimization and Trial Matching Tools, Drug Discovery AI
By Cancer Type	Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Hematologic Malignancies
By Technology	Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, Reinforcement Learning
By End User	Hospitals and Cancer Centers, Biopharma Companies, Research Institutes, Startups, Government Agencies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising adoption of AI-assisted cancer diagnosis and treatment planning; growing availability of multi-omics and clinical data for precision oncology models; increasing demand for personalized therapies, clinical trial optimization, and faster drug discovery workflows
Customization Option	Available upon request